+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“30% of the Top Generic Drug Producers are in the ROW region” says new Visiongain report

31 January 2019
Pharma

Visiongain has launched a new pharma report Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029 : North America, Europe, India, Rest of the World (RoW).

This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017. It analyses the leading companies operating in the generic drug market and discusses forces that shape companies’ strategic directions. There have been a number of consolidation activities, mergers, acquisitions and divestitures occurring amongst the leading players in the generic drugs market over the last few years. This level of corporate activities has led to the creation of a market which is steep in growth opportunities for companies that are able to align their strategies to growth.

The lead analyst of the report commented "Related to the move towards biosimilars and the decreasing distance between originator and generic companies is the rise of the complex generics sector. As generics competition steadily increases in all markets, there are strong incentives for companies with sufficiently advanced technologies to move beyond simple generics into more complex, higher-margin products.

With differentiation likely to increase in importance as the generics market becomes more competitive, novel delivery systems and reformulations (for example, extended-release versions of original products) will also increase in significance for generics companies. Competitive strength in this field will require investment in ongoing R&D, further contributing to the closure of the gap between original and generic manufacturers."

Leading companies featured in the report include Abbott, Aurobindo, EMS, Endo, Fresenius, Kabi, Mylan, Novartis (Sandoz), Pfizer, Sun Pharmaceuticals, Teva.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read